Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
about
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitorsTargeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinomaHedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulnessSpotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.Vismodegib: the proof of concept in Basal cell carcinoma.Vismodegib: in locally advanced or metastatic basal cell carcinoma.Hedgehog pathway as a drug target: Smoothened inhibitors in development.Vismodegib.Cholesterol: its regulation and role in central nervous system disorders.Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjectsInhibition of Gli/hedgehog signaling in prostate cancer cells by "cancer bush" Sutherlandia frutescens extract.Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor VismodegibThe dawn of hedgehog inhibitors: Vismodegib.Profile of vismodegib and its potential in the treatment of advanced basal cell carcinomaTargeting hedgehog signaling in cancer: research and clinical developments.Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.Peptide targeted lipid nanoparticles for anticancer drug delivery.The utility of hedgehog signaling pathway inhibition for cancer.Hedgehog signaling pathway and cancer therapeutics: progress to date.Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomasVismodegib in the treatment of basal cell carcinoma: indications for clinical practice.Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.Vismodegib: a promising drug in the treatment of basal cell carcinomas.Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Advances in targeting the Hedgehog signaling pathway in cancer therapy.Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
P2860
Q26775917-8BA3EC69-1E17-44FE-85E8-F9F3F62BAC2EQ26995961-E834F0BC-E8B4-40FB-8A8C-9B2D9404DCFEQ28072902-B33CE410-74D7-4DB6-98B8-8905A7A1E229Q33703696-D7462438-87AB-479B-B557-F187B7151259Q33734736-2C658AA6-5ACB-41A8-9309-76D6C3D1C045Q34032755-EC06DAB3-F3EC-45B9-A753-C9A02E3740EAQ35885181-95EC13CC-BDE2-4C6C-AD9D-4B5F07DF8943Q36059884-7C2C06CD-3AAE-4580-BFA0-5D7A53912D0FQ36355194-96BE457E-7113-4D35-B12C-ECEA7EAEDC75Q36390239-7CC008A0-259A-4696-B378-89655B93856FQ36463996-7862773D-380E-44C7-8039-B59710E696E9Q36473104-73552A3B-3048-4AE5-BA67-F930A8E444F4Q36813809-D5A9CFD9-48C2-4C6E-9F32-D24E8359DF0BQ37079100-9EA4CE33-2F76-4361-88E6-481B7EB24048Q37232227-B88BFD4A-0FC0-4420-85CE-FCBA71508F6DQ37375947-32453F93-C897-4BED-A33D-2089B8EBC069Q37551492-01E91901-467F-4D0C-B490-F6B343BD72ECQ38016810-6E12C4B0-2BFF-4BEA-96F5-2D01553A09F5Q38031211-B8EB1E17-8098-447A-8BF9-809D91B7C54CQ38100713-F820B83C-354C-424F-8F7E-919BF1898DE0Q38164659-918160D2-7EC9-4D62-B105-767CA0CAA041Q38230602-2553C9B6-7B63-4319-876A-E40FA81CE5A8Q38231365-45741054-9231-4631-8E00-6DD8873CC365Q38251864-9AD9641F-16DE-4AC3-8483-CE8B876B19C7Q38465861-E7166B12-3015-423C-8D58-30741FEFE690Q38605886-D8125F5A-C4F2-4CD6-B9EA-5371889D7456Q38836071-AFA002A9-3E07-485D-B714-4E40AF72BD0BQ38990833-D38EB099-3A03-495C-829C-A7B628879B9DQ39173896-6EF422D3-6152-400D-A534-719294E9E6DAQ39568979-76BF68B7-712A-49F7-B1F6-C34D7B2E045DQ42514120-E3CC6755-AA16-465B-B2A9-4809E622EB1FQ42514766-84253975-7607-4EDD-B6C3-A9E5CFE9571AQ43850449-3C766ACA-0641-40B7-BFB7-0EE9874525FDQ45982851-7D274081-3CB0-410F-AA6E-9D9316B50200
P2860
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Pharmacokinetic dose-schedulin ...... ed or metastatic solid tumors.
@en
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib
@nl
type
label
Pharmacokinetic dose-schedulin ...... ed or metastatic solid tumors.
@en
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib
@nl
prefLabel
Pharmacokinetic dose-schedulin ...... ed or metastatic solid tumors.
@en
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib
@nl
P2093
P1476
Pharmacokinetic dose-schedulin ...... ed or metastatic solid tumors.
@en
P2093
Alex Adjei
Antonio Jimeno
Dawn Colburn
Ilsung Chang
Jennifer A Low
Jordan Berlin
Lawrence Leichman
Patricia M Lorusso
P304
P356
10.1158/1078-0432.CCR-11-0972
P407
P577
2011-07-13T00:00:00Z